Zanubrutinib

Zanubrutinib (BGB3111) is a potent, selective and orally available Btk inhibitor; displaysmuch more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib. BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.